CRANBURY, N.J.--(BUSINESS WIRE)--Physicians’ Education Resource® (PER®), the nation’s leading resource for oncology and hematology continuing medical education (CME), will host its second annual Precision Medicine Through Plasma: Using Liquid Biopsies in Contemporary Oncology Care workshop on Saturday, Dec. 8 at the Convene in New York City. The workshop will be chaired by Benjamin P. Levy, M.D., thoracic medical oncologist and the clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, Associate Professor, Johns Hopkins University School of Medicine.
“The introduction of liquid biopsies and plasma genotyping has drastically altered the diagnostic algorithm for patients with multiple solid tumor malignancies. These platforms not only have the ability to accurately identify the genetic underpinnings of a tumor but may also have utility to assess response to therapy in real time as well as detect minimal residual disease (MRD) in patients who have undergone curative intent therapy. This meeting is unique in brining together disease-specific experts who will each highlight the role and promise of liquid biopsies within their discipline,” Levy said.
The following key experts in lung, breast, and gastrointestinal malignancies will provide an overview of the latest clinical data on liquid biopsies, followed by detailed, real-world and practical case-based discussions among a multidisciplinary faculty:
- Ryan B. Corcoran, M.D., Ph.D., scientific director, Termer Center for Targeted Therapy, director gastrointestinal cancer center program, Massachusetts General Hospital Cancer Center
- Massimo Cristofanilli, M.D., FACP, professor of medicine, division of hematology and oncology, Northwestern University Feinberg School of Medicine, associate director, translational research and precision medicine, director, OncoSET precision medicine program, Robert H. Laurie Comprehensive Cancer Center
- Balazs Halmos, M.D., M.S., professor of clinical medicine, director of thoracic/head and neck oncology, director, clinical cancer genomic, Albert Einstein College of Medicine/Montefiore Medical Center
- Bob T. Li, M.D., M.P.H., medical oncologist, thoracic oncology and early drug development service, Memorial Sloan Kettering Cancer Center
- Geoffrey R. Oxnard, M.D., physician, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School
- Joseph A. Sparano, M.D., professor, department of medicine, obstetrics, gynecology and women’s health, Albert Einstein College of Medicine, associate director for clinical research, Albert Einstein Cancer Center, , associate chairman for clinical research, department of oncology, Montefiore Medical Center
- John H. Strickler, M.D., assistant professor of medicine, Duke University School of Medicine.
“It is very important for medical professionals to not only be aware of the various actionable mutations, but also the methods to identify these mutations,” said Phil Talamo, president of PER.® “We look forward to offering this live CME workshop for the second year where attendees will get the chance to gather, interact and learn more about providing better patient care at each point along the disease continuum.”
This half-day live interactive educational CME/CE workshop will address the rapidly evolving science and associated therapeutic developments resulting from the emergence of novel testing strategies such as liquid biopsies. Attendees will have the opportunity to increase their confidence and competence in selecting emerging novel testing strategies, such as liquid biopsies and plasma testing, as you strive to provide the best care for your patients. Ample question-and-answer time will also be provided for attendees to interact directly with the expert faculty.
The activity offers AMA PRA Category 1 Credit.™ For registration and more information, visit https://www.gotoper.com/conferences/pmlb/meetings/2nd-annual-precision-medicine-through-plasma-using-liquid-biopsies-in-contemporary-oncology-care.
About Physicians’ Education Resource® (PER®)
Since 1995, PER® has been dedicated to advancing cancer care through professional education and now furthers patient care and treatment strategies on a wide variety of chronic illnesses and diseases. In 2016, PER® initiated continuing medical education (CME) programming in the cardiovascular and endocrinology areas and continues to grow its therapeutic reach outside of oncology. While continuing to expand into topics outside of oncology, PER® remains the leading provider of live, online and print CME activities related to oncology and hematology. The high-quality, evidence-based activities feature leading distinguished experts who focus on the application of practice-changing advances. In 2018, PER® will develop and implement 21 historic annual legacy conferences in the United States and Europe, along with many renowned online learning formats. PER® is accredited by the Accreditation Council for Continuing Medical Education and the California Board of Registered Nursing. PER® is part of the Cranbury, New Jersey-based MJH Associates Inc. family of businesses. Learn more at http://www.gotoper.com and http://www.mjhassoc.com.
